Eledon Pharmaceuticals, Inc.

NasdaqCM:ELDN Stok Raporu

Piyasa değeri: US$277.8m

Eledon Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Eledon Pharmaceuticals CEO'su DA Gros, Sep2020 tarihinde atandı, in görev süresi 4.17 yıldır. in toplam yıllık tazminatı $ 2.55M olup, şirket hissesi ve opsiyonları dahil olmak üzere 21.9% maaş ve 78.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.022% ine doğrudan sahiptir ve bu hisseler $ 60.42K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.6 yıl ve 5.9 yıldır.

Anahtar bilgiler

DA Gros

İcra Kurulu Başkanı

US$2.6m

Toplam tazminat

CEO maaş yüzdesi21.9%
CEO görev süresi4.2yrs
CEO sahipliği0.02%
Yönetim ortalama görev süresi3.6yrs
Yönetim Kurulu ortalama görev süresi5.9yrs

Son yönetim güncellemeleri

Recent updates

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Mar 22
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Dec 05
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Aug 10
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Apr 27
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Jan 05
Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Eledon adds 10% as FDA clears clinical trial for kidney disease candidate

Sep 06

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Aug 31
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Eledon gets FDA nod to start trial of organ rejection preventing therapy

Aug 01

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Jul 18

Eledon gives update on development strategy for AT-1501 in renal transplantation

Apr 26

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Apr 14
Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Feb 21
What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Dec 30
Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Novus Therapeutics (NVUS) Investor Presentation - Slideshow

Dec 18

Novus Therapeutics EPS misses by $3.76

Nov 16

Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease

Nov 02

CEO Tazminat Analizi

DA Gros'un ücretlendirmesi Eledon Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$109m

Mar 31 2024n/an/a

-US$129m

Dec 31 2023US$3mUS$559k

-US$117m

Sep 30 2023n/an/a

-US$145m

Jun 30 2023n/an/a

-US$145m

Mar 31 2023n/an/a

-US$89m

Dec 31 2022US$1mUS$533k

-US$88m

Sep 30 2022n/an/a

-US$38m

Jun 30 2022n/an/a

-US$38m

Mar 31 2022n/an/a

-US$36m

Dec 31 2021US$748kUS$504k

-US$35m

Sep 30 2021n/an/a

-US$32m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$7mUS$150k

-US$23m

Tazminat ve Piyasa: DA 'nin toplam tazminatı ($USD 2.55M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.46M ).

Tazminat ve Kazançlar: DA şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

DA Gros (52 yo)

4.2yrs

Görev süresi

US$2,553,153

Tazminat

Dr. David-Alexandre C. Gros, also known as DA, M.D., Ph D., serves as Chief Executive Officer and Non-Independent Director at Eledon Pharmaceuticals, Inc. since September 09, 2020. Dr. Gros served as an ad...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
David-Alexandre Gros
CEO & Non Independent Director4.2yrsUS$2.55m0.022%
$ 60.4k
Steven Perrin
President4.2yrsUS$1.54m0.0024%
$ 6.7k
Paul Little
Chief Financial Officer3.7yrsUS$1.32m0.024%
$ 67.1k
John Herberger
Vice President of Technical Operations2.5yrsVeri yokVeri yok
Bryan Smith
General Counsel3.6yrsUS$1.68m0%
$ 0
David Hovland
Chief Regulatory Officer3.6yrsVeri yokVeri yok
Eliezer Katz
Chief Medical Officer1.1yrsVeri yokVeri yok

3.6yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: ELDN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.6 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
David-Alexandre Gros
CEO & Non Independent Director4.2yrsUS$2.55m0.022%
$ 60.4k
Steven Perrin
President4.2yrsUS$1.54m0.0024%
$ 6.7k
Keith Katkin
Independent Chairman of the Board7.5yrsUS$1.52m0.0016%
$ 4.6k
John McBride
Independent Director7.5yrsUS$371.82k0%
$ 0
James Robinson
Independent Director1.1yrsUS$201.79kVeri yok
June Lee
Independent Director3.9yrsUS$374.44k0%
$ 0
Hamid Djalilian
Member of Scientific Advisory Board5.9yrsVeri yokVeri yok
Paola Marchisio
Member of Scientific Advisory Board5.9yrsVeri yokVeri yok
Tal Marom
Member of Scientific Advisory Board5.9yrsVeri yokVeri yok
Michael Pichichero
Member of Scientific Advisory Board5.9yrsVeri yokVeri yok
Anne Schilder
Member of Scientific Advisory Board5.9yrsVeri yokVeri yok
Seth Pranksy
Member of Scientific Advisory Board5.9yrsVeri yokVeri yok

5.9yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ELDN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.9 yıldır).